SCHEDULE: Adage Capital Discloses 4.5% Stake in Fulcrum Therapeutics
Beneficial Ownership Report
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 4.5% beneficial ownership stake in Fulcrum Therapeutics, Inc. as of September 30, 2025.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 2,432,000 shares of Fulcrum Therapeutics, Inc. common stock.
- This represents 4.5% of the company's outstanding common stock.
- The percentage is calculated based on 54,091,588 shares outstanding as of July 22, 2025, as reported in Fulcrum Therapeutics' Quarterly Report on Form 10-Q for the period ended June 30, 2025.
- The reporting persons share both voting and dispositive power over all 2,432,000 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine disclosure filing (Schedule 13G) by an institutional investor, indicating a beneficial ownership stake. It does not contain operational or financial performance data, nor does it suggest any significant positive or negative developments for the issuer. The sentiment is neutral as it's purely informational.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance from the reporting persons or the issuer.
Industry Context
This filing indicates a significant institutional investor, Adage Capital Management, maintains a substantial stake in Fulcrum Therapeutics, a biotechnology company. Such disclosures are routine for large investors and provide transparency into major holdings within the sector, but do not inherently signal specific industry trends or competitive shifts.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holding, which can influence market perception of institutional confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 2025-07-22 | Date used for calculating total shares outstanding (54,091,588 shares) as reported in the Company's Q2 2025 Form 10-Q. |
| 2025-07-29 | Date Fulcrum Therapeutics filed its Quarterly Report on Form 10-Q for the period ended June 30, 2025. |
| 2025-09-30 | Date of the event which required the filing of this Schedule 13G, reflecting the beneficial ownership. |
| 2025-11-13 | Date the Schedule 13G Amendment No. 2 was signed and filed by the Reporting Persons. |
Keywords
Fulcrum Therapeutics, Adage Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.